Dulaglutide/ja: Difference between revisions

(One intermediate revision by the same user not shown)

Line 134:

デュラグルチドの安全性と有効性は、3,342人の2型糖尿病患者を対象とした6つの臨床試験で評価された。デュラグルチドを投与された被験者は、HbA1c値（ヘモグロビンA1cは血糖コントロールの指標）の低下により観察されるように、血糖コントロールの改善を認めた。

~~<div lang="en" dir="ltr" class="mw-content-ltr">~~

米国[[Food and Drug Administration/ja|食品医薬品局]]（FDA）はデュラグルチドを[[Risk Evaluation and Mitigation Strategies/ja|リスク評価と軽減戦略]]（REMS）付きで承認し、[[Eli Lilly and Company|イーライリリー・アンド・カンパニー]]にトルリシティの承認を認めた。REMSは、膵炎のリスクと薬物に関連する[[medullary thyroid carcinoma/ja|甲状腺髄様癌]]の潜在的なリスクを医師に認識させるためにイーライリリーがとるいくつかのステップから構成されている。

~~The U.S.~~ [[Food and Drug Administration]] ~~(FDA) approved dulaglutide with a~~ [[Risk Evaluation and Mitigation Strategies|~~Risk Evaluation and Mitigation Strategy~~]] ~~(REMS), and granted the approval of Trulicity to~~ [[Eli Lilly and Company]]~~. The REMS consists of a number of steps that Eli Lilly will take to make physicians aware of the risk of pancreatitis and the potential risk of~~ [[medullary thyroid carcinoma]] ~~associated with the drug.~~

~~</div>~~

~~<div lang="en" dir="ltr" class="mw~~-~~content-ltr">~~

2020年、FDAはAWARD-11試験の結果に基づいて、3.0 mgと4.5 mgの2種類の高用量医薬品を承認した。

~~In 2020, the FDA approved two higher doses of the medication, 3~~.0 ~~mg and 4~~.5 ~~mg, based on results of the AWARD-11 trial demonstrating improved glucose lowering and weight benefits.~~

~~</div>~~

~~<div lang="en" dir="ltr" class="mw-content-ltr">~~

== Further reading ==

* {{cite journal | vauthors = Scott LJ | title = Dulaglutide: A Review in Type 2 Diabetes | journal = Drugs | volume = 80 | issue = 2 | pages = 197–208 | date = February 2020 | pmid = 32002850 | doi = 10.1007/s40265-020-01260-9 | s2cid = 210954338 }}

* {{cite journal | vauthors = Edwards KL, Minze MG | title = Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes | journal = Core Evidence | volume = 10 | pages = 11–21 | date = 2015 | pmid = 25657615 | pmc = 4295897 | doi = 10.2147/CE.S55944 | doi-access = free }}

* {{cite journal | vauthors = Romera I, Cebrián-Cuenca A, Álvarez-Guisasola F, Gomez-Peralta F, Reviriego J | title = A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes | journal = Diabetes Therapy | volume = 10 | issue = 1 | pages = 5–19 | date = February 2019 | pmid = 30506340 | pmc = 6349277 | doi = 10.1007/s13300-018-0535-9 }}

~~</div>~~

~~<div lang="en" dir="ltr" class="mw-content-ltr">~~

~~</div>~~

~~<div lang="en" dir="ltr" class="mw-content-ltr">~~

~~{{二次利用|date=7 February 2024}}~~

[[Category:Drugs developed by Eli Lilly and Company]]

[[Category:GLP-1 receptor agonists]]

[[Category:Peptide therapeutics]]

~~</div>~~

@@ Line 134: / Line 134: @@
 デュラグルチドの安全性と有効性は、3,342人の2型糖尿病患者を対象とした6つの臨床試験で評価された。デュラグルチドを投与された被験者は、HbA1c値（ヘモグロビンA1cは血糖コントロールの指標）の低下により観察されるように、血糖コントロールの改善を認めた。
-<div lang="en" dir="ltr" class="mw-content-ltr">
+米国[[Food and Drug Administration/ja|食品医薬品局]]（FDA）はデュラグルチドを[[Risk Evaluation and Mitigation Strategies/ja|リスク評価と軽減戦略]]（REMS）付きで承認し、[[Eli Lilly and Company|イーライリリー・アンド・カンパニー]]にトルリシティの承認を認めた。REMSは、膵炎のリスクと薬物に関連する[[medullary thyroid carcinoma/ja|甲状腺髄様癌]]の潜在的なリスクを医師に認識させるためにイーライリリーがとるいくつかのステップから構成されている。
-The U.S. [[Food and Drug Administration]] (FDA) approved dulaglutide with a [[Risk Evaluation and Mitigation Strategies|Risk Evaluation and Mitigation Strategy]] (REMS), and granted the approval of Trulicity to [[Eli Lilly and Company]]. The REMS consists of a number of steps that Eli Lilly will take to make physicians aware of the risk of pancreatitis and the potential risk of [[medullary thyroid carcinoma]]  associated with the drug.
-</div>
-<div lang="en" dir="ltr" class="mw-content-ltr">
+年、FDAはAWARD-11試験の結果に基づいて、3.0&nbsp;mgと4.5&nbsp;mgの2種類の高用量医薬品を承認した。
-In 2020, the FDA approved two higher doses of the medication, 3.0&nbsp;mg and 4.5&nbsp;mg, based on results of the AWARD-11 trial demonstrating improved glucose lowering and weight benefits.
-</div>
-<div lang="en" dir="ltr" class="mw-content-ltr">
 == Further reading ==
 * {{cite journal | vauthors = Scott LJ | title = Dulaglutide: A Review in Type 2 Diabetes | journal = Drugs | volume = 80 | issue = 2 | pages = 197–208 | date = February 2020 | pmid = 32002850 | doi = 10.1007/s40265-020-01260-9 | s2cid = 210954338 }}
 * {{cite journal | vauthors = Edwards KL, Minze MG | title = Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes | journal = Core Evidence | volume = 10 | pages = 11–21 | date = 2015 | pmid = 25657615 | pmc = 4295897 | doi = 10.2147/CE.S55944 | doi-access = free }}
 * {{cite journal | vauthors = Romera I, Cebrián-Cuenca A, Álvarez-Guisasola F, Gomez-Peralta F, Reviriego J | title = A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes | journal = Diabetes Therapy | volume = 10 | issue = 1 | pages = 5–19 | date = February 2019 | pmid = 30506340 | pmc = 6349277 | doi = 10.1007/s13300-018-0535-9 }}
-</div>
-<div lang="en" dir="ltr" class="mw-content-ltr">
+{{Oral hypoglycemics and insulin analogs/ja|state=expanded}}
-{{Oral hypoglycemics and insulin analogs|state=expanded}}
 {{Portal bar | Medicine}}
-</div>
-<div lang="en" dir="ltr" class="mw-content-ltr">
-{{二次利用|date=7 February 2024}}
 [[Category:Drugs developed by Eli Lilly and Company]]
 [[Category:GLP-1 receptor agonists]]
 [[Category:Peptide therapeutics]]
-</div>